C-peptide and captopril are equally effective in lowering glomerular hyperfiltration in diabetic rats.

• 150042582004051920040921200611150931-05091962004JunNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal AssociationNephrol. Dial. Transplant.C-peptide and captopril are equally effective in lowering glomerular hyperfiltration in diabetic rats.1385-91BACKGROUND: C-peptide has been shown to reduce glomerular hyperfiltration, glomerular hypertrophy and urinary albumin excretion in type 1 diabetes, but its effect has not been compared with that of an angiotensin-converting enzyme inhibitor (ACEI) in the early stage of renal involvement in diabetes. METHODS: Glomerular filtration rate (GFR) was measured in terms of inulin clearance and renal blood flow, using ultrasound technique, in four groups of streptozotocin-induced diabetic rats before and after a 60 min infusion of C-peptide (D-Cp), captopril (D-ACEI), C-peptide and captopril (D-Cp-ACEI) or placebo (D-placebo). In addition, a non-diabetic control group was studied before and after captopril infusion (C-ACEI). RESULTS: GFR was 37-51% higher in the diabetic groups than in the control animals. GFR decreased after treatment in the D-Cp, D-ACEI and D-Cp-ACEI groups, but did not change in the D-placebo group. Blood flow increased by 26-32% in the three groups receiving captopril and by 5% in the diabetic groups treated with C-peptide alone or placebo. The increase in blood flow in the three ACEI-treated groups was significantly greater than in the D-placebo group. Filtration fraction fell significantly in all groups, but only in the combined D-Cp-ACEI group did it fall significantly more than in the D-placebo group. CONCLUSIONS: C-peptide and captopril lower diabetes-induced glomerular hyperfiltration to a similar extent, but the influence of captopril on blood flow is greater than that of C-peptide, suggesting different mechanisms of action. No statistically significant additive effects of C-peptide and captopril were shown in this acute infusion study.Department of Nephrology, Danderyd Hospital, SE-182 88 Stockholm, Sweden. bjorn.samnegard@medks.ki.seSamnegårdBjörnBJacobsonStefan HSHJohanssonBo-LennartBLEkbergKarinKIsakssonBrittaBWahrenJohnJSjöquistMatsMengComparative StudyJournal Article20040305EnglandNephrol Dial Transplant87064020Angiotensin-Converting Enzyme Inhibitors0C-Peptide62571-86-2CaptoprilIMAngiotensin-Converting Enzyme InhibitorspharmacologyAnimalsC-PeptidepharmacologyCaptoprilpharmacologyDiabetes Mellitus, ExperimentalphysiopathologyGlomerular Filtration Ratedrug effectsKidney Glomerulusdrug effectsphysiopathologyMaleRatsRats, Sprague-DawleyRegional Blood Flowdrug effects200439502004924502004Mar5ppublish1500425810.1093/ndt/gfh163gfh163

Nyckelord

Angiotensin-Converting Enzyme Inhibitors/*pharmacology

Animals

C-Peptide/*pharmacology

Captopril/*pharmacology

Diabetes Mellitus; Experimental/*physiopathology

Glomerular Filtration Rate/*drug effects

Kidney Glomerulus/*drug effects/*physiopathology

Male

Rats

Rats; Sprague-Dawley

Regional Blood Flow/drug effects

Publikations- och innehållstyp

vet (ämneskategori)

art (ämneskategori)